| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 3.74 | 36.5% |
| Total Income | 3.74 | 36.5% |
| Expenditure | 17.56 | 0.6% |
| PBT | -15.13 | 9.7% |
| Net Profit | -15.20 | 427.6% |
| OPM | — | |
| NPM | — | |
| EPS | -3.76 | 7620.0% |
Kyntra Bio Reports Q1 2026 Financial Results
12 May 2026 · 12 May, 1:43 am
Summary
Kyntra Bio reported financial results for the first quarter of 2026, with total revenue from continuing operations at $3.7 million compared to $2.7 million in the first quarter of 2025. The net loss from continuing operations was $15.1 million, or $3.74 net loss per basic and diluted share. The company's cash, cash equivalents, investments, and accounts receivable totaled $100.3 million as of March 31, 2026, expected to fund operating plans into 2028. The company is progressing with clinical trials for FG-3246 and finalizing the protocol for the pivotal Phase 3 trial of roxadustat.
Key Highlights
- 1
Kyntra Bio reported total revenue from continuing operations for the first quarter of 2026 was $3.7 million, compared to $2.7 million for the first quarter of 2025.
- 2
The company's net loss from continuing operations for the first quarter of 2026 was $15.1 million, or $3.74 net loss per basic and diluted share.
- 3
As of March 31, 2026, Kyntra Bio reported $100.3 million in cash, cash equivalents, investments, and accounts receivable.
- 4
The company expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund operating plans into 2028.
- 5
The Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer is progressing well, with the interim analysis anticipated in 4Q 2026.
- 6
The pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes is being finalized following feedback from the FDA.
Management Comments
Thane Wettig
“In the first quarter, we continued to make steady progress across our pipeline. We are encouraged by the pace of enrollment in our Phase 2 trial of FG-3246 in patients with mCRPC and are on track for the interim analysis in the fourth quarter of 2026. We remain confident in the potential of FG-3246 to deliver competitive progression free survival results in the Phase 2 monotherapy trial. In addition, following FDA feedback, we are finalizing the protocol for the pivotal Phase 3 trial of roxadustat for the treatment of lower-risk MDS, and anticipate trial initiation in the second half of 2026.”
Informational and educational content only. Not investment advice.